{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:48:35Z","timestamp":1764240515461,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corp","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-022-02094-5","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T07:04:02Z","timestamp":1649660642000},"page":"2668-2687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison"],"prefix":"10.1007","volume":"39","author":[{"given":"Raul","family":"Cordoba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Prawitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Westley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Ambarkhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-9306","authenticated-orcid":false,"given":"Lorenzo","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","volume":"30","author":"AI Shaffer","year":"2012","unstructured":"Shaffer AI, Young R, Staudt L. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565\u2013610.","journal-title":"Annu Rev Immunol"},{"key":"2094_CR2","first-page":"5","volume":"9","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci (Basel). 2021;9:5.","journal-title":"Med Sci (Basel)"},{"key":"2094_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817\u201326.","journal-title":"Lancet"},{"key":"2094_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561\u201376.","journal-title":"Ann Oncol"},{"unstructured":"National Comprehensive Cancer Network. NCCN Guidelines\u00ae B-Cell Lymphomas Version 4.2021, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (2021, Accessed September 30, 2021).","key":"2094_CR5"},{"key":"2094_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15:931\u201342.","journal-title":"Lancet Oncol"},{"unstructured":"SEER Cancer Stat Facts. Diffuse Large B-Cell Lymphoma. National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html (SEER 18 2011\u20132017, Accessed January 26, 2022).","key":"2094_CR7"},{"key":"2094_CR8","doi-asserted-by":"publisher","first-page":"8553","DOI":"10.3390\/ijms21228553","volume":"21","author":"LJ Harris","year":"2020","unstructured":"Harris LJ, Patel K, Martin M. Novel therapies for relapsed or refractory diffuse large B-cell lymphoma. Int J Mol Sci. 2020;21:8553.","journal-title":"Int J Mol Sci"},{"key":"2094_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood"},{"key":"2094_CR10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1158\/1078-0432.CCR-12-2837","volume":"19","author":"C Sarkozy","year":"2013","unstructured":"Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res. 2013;19:1660\u20139.","journal-title":"Clin Cancer Res"},{"unstructured":"US FDA. MONJUVI\u00ae (tafasitamab-cxix) for injection, for intravenous use, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761163s001lbl.pdf (2021, Accessed September 30, 2021).","key":"2094_CR11"},{"key":"2094_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-021-00456-w","volume":"11","author":"BD Cheson","year":"2021","unstructured":"Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021;11:68.","journal-title":"Blood Cancer J"},{"key":"2094_CR13","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","volume":"106","author":"J Duell","year":"2021","unstructured":"Duell J, Maddocks KJ, Gonz\u00e1lez-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106:2417\u201326.","journal-title":"Haematologica"},{"unstructured":"Incyte Biosciences Distribution B.V. MINJUVI (tafasitamab) 200 mg powder for concentrate for solution for infusion, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/minjuvi-epar-product-information_en.pdf (2021, Accessed September 30, 2021).","key":"2094_CR14"},{"unstructured":"European Medicines Agency (EMA). Public summary of opinion on orphan designation - humanised Fc engineered monoclonal antibody against CD19 for the treatment of diffuse large B-cell lymphoma, https:\/\/www.ema.europa.eu\/en\/documents\/orphan-designation\/eu\/3\/14\/1424-public-summary-opinion-orphan-designation-humanised-fc-engineered-monoclonal-antibody-against_en.pdf (2015, Accessed September 30, 2021).","key":"2094_CR15"},{"key":"2094_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020;21:978\u201388.","journal-title":"Lancet Oncol"},{"doi-asserted-by":"crossref","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u201325.","key":"2094_CR17","DOI":"10.1093\/annonc\/mdv304"},{"unstructured":"Britannica - The Editors of Encyclopaedia. Leaf-nosed bat, http:\/\/www.britannica.com\/EBchecked\/topic\/693386\/leaf-nosed-bat (2009, Accessed September 30, 2021).","key":"2094_CR18"},{"key":"2094_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/WNR.0b013e3282f52c61","volume":"19","author":"PHS Jen","year":"2008","unstructured":"Jen PHS, Wu CH. Echo duration selectivity of the bat varies with pulse-echo amplitude difference. Neuroreport. 2008;19:373\u20137.","journal-title":"Neuroreport"},{"doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","key":"2094_CR20","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2094_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE, http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2017\/05\/Population-adjustment-TSD-FINAL.pdf (2016, Accessed September 30, 2021).","key":"2094_CR22"},{"key":"2094_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"2094_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the cox model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York: Springer; 2000."},{"unstructured":"Therneau T. A Package for Survival Analysis in R. R package version 3.2\u20133, https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html (2020, Accessed January 28, 2022).","key":"2094_CR25"},{"key":"2094_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"2094_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v011.i10","volume":"11","author":"A Zeileis","year":"2004","unstructured":"Zeileis A. Econometric computing with HC and HAC covariance matrix estimators. J Stat Softw. 2004;11:1\u201317.","journal-title":"J Stat Softw"},{"key":"2094_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v016.i09","volume":"16","author":"A Zeileis","year":"2006","unstructured":"Zeileis A. Object-oriented computation of sandwich estimators. J Stat Softw. 2006;16:1\u201316.","journal-title":"J Stat Softw"},{"key":"2094_CR29","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.","journal-title":"BMJ."},{"key":"2094_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020;38:155\u201365.","journal-title":"J Clin Oncol"},{"unstructured":"US FDA. Statistical review and evaluation: POLIVY (polatuzumab vedotin), https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761121Orig1s000StatR.pdf (2019, Accessed September 30, 2021).","key":"2094_CR31"},{"key":"2094_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93:403\u20139.","journal-title":"Ann Hematol"},{"key":"2094_CR33","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103\u20139.","journal-title":"J Clin Oncol"},{"key":"2094_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int J Technol Assess Health Care. 2019;35:221\u20138.","journal-title":"Int J Technol Assess Health Care"},{"key":"2094_CR35","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.1016\/S2152-2650(21)01891-7","volume":"21","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Yoon DH, Mondello P, et al. ABCL-346: overall survival with tafasitamab + lenalidomide (LEN) vs routinely administered therapies for ASCT-ineligible relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): outcomes from the observational RE-MIND2 study. Clin Lymphoma Myeloma Leuk. 2021;21:S392\u20133.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2094_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1182\/blood-2021-148302","volume":"138","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Yoon DH, Mondello P, et al. Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T: comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2021;138:183.","journal-title":"Blood"},{"key":"2094_CR37","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood-2018-99-118551","volume":"132","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): updated results of a phase (Ph) Ib\/II study. Blood. 2018;132:1683.","journal-title":"Blood"},{"key":"2094_CR38","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/blood-2019-123449","volume":"134","author":"LH Sehn","year":"2019","unstructured":"Sehn LH, Matasar MJ, Flowers CR, et al. Polatuzumab vedotin plus bendamustine with rituximab in relapsed\/refractory diffuse large B-cell lymphoma: updated results of a phase Ib\/II randomized study. Blood. 2019;134:4081.","journal-title":"Blood"},{"doi-asserted-by":"crossref","unstructured":"Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98:1726\u201331.","key":"2094_CR39","DOI":"10.3324\/haematol.2013.090597"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02094-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:36:12Z","timestamp":1653042972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02094-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02094-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}